Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
86.70
-2.34 (-2.63%)
NASDAQ · Last Trade: Jul 12th, 2:27 AM EDT
Detailed Quote
Previous Close
89.04
Open
89.59
Bid
86.70
Ask
90.00
Day's Range
86.25 - 90.36
52 Week Range
40.61 - 94.80
Volume
1,105,405
Market Cap
5.51B
PE Ratio (TTM)
-30.85
EPS (TTM)
-2.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
953,738
Chart
About Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on transforming the treatment paradigm for people with rare metabolic disorders, particularly those related to obesity and appetite regulation. The company is dedicated to advancing its research and development efforts to create therapies that target the underlying causes of these conditions. By leveraging innovative science and its expertise in the genetic basis of obesity, Rhythm aims to develop effective treatments that improve the quality of life for patients and address significant unmet medical needs in the field of metabolic health. Read More
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced the pricing of its upsized public offering of 2,058,824 shares of its common stock at a public offering price of $85.00 per share. In addition, Rhythm also granted the underwriters a 30-day option to purchase up to an additional 308,823 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Rhythm, and excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are being offered by Rhythm. The offering is expected to close on or about July 11, 2025, subject to the satisfaction of customary closing conditions.
BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks --
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences:
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.
